Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Rogers is an expert in Pulmonary and Critical Care Medicine. She has practiced in these fields for 10 years. She has a special interest in ICU medicine, with a research focus on acute respiratory failure and ARDS. She researchers in blood biomarkers of these diseases, and is very active in teaching residents and fellows about critical care.
We use genetics and genomics methodologies to identify novel ARDS pathobiology; we hope that this will enable identification of novel biomarkers, phenotypes, and treatments for the disease. We are building a plasma biobank of critically ill patients at Stanford, with a particular focus on metabolic changes in critical illness.
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial
(NCT04501978) at selected study sites who receive certain pre-specified, blinded
investigational agents or placebo as part of that trial and who have since achieved sustained
recovery from COVID-19 and meet certain criteria, including not having received a COVID-19
vaccination since enrollment, will be randomized to one of four groups to receive the Moderna
mRNA-1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines). No "dummy/placebo" vaccine will be
Choice of Moderna or Pfizer vaccine is determined based on availability at the site. The
choice is individual, although participants vaccinated twice should receive the same type of
vaccine when receiving two injections. The study's objective is to evaluate if the vaccine is
best administered early or deferred after recovery, and whether one injection provides
comparable immune response to a two injection course of vaccination. Participants will remain
blinded to the interventions received in the ACTIV-3/TICO study, however allocation to the
timing of vaccination and to one or two vaccinations in this (VATICO) study is not blinded.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and
safety of different investigational therapeutics among adults who have COVID-19 but are not
yet sick enough to require hospitalization. The overall hypothesis is that through an
adaptive trial design, potential effective therapies (single and combination) may be
identified for this group of patients.
COVID-19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform protocol
designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding
(Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the
platform, every investigational product will collect data for both Domain primary endpoints.
Individual treatments to be evaluated in the platform will be described in separate
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
ACTIV-3: Therapeutics for Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in
people who have been hospitalized with the infection. Participants in the study will be
treated with either a study drug plus current standard of care (SOC), or with placebo plus
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled
corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory
failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid
treatment strategies in the first 24 hours for patients with sepsis-induced hypotension. The
aim of the study is to determine the impact of a restrictive fluids strategy (vasopressors
first followed by rescue fluids) as compared to a liberal fluid strategy (fluids first
followed by rescue vasopressors) on 90-day in-hospital mortality in patients with